Total Payments
$524,415
2024 Payments
$16,653
Companies
12
Transactions
177
Medicare Patients
3,000
Medicare Billing
$2.3M
Payment Breakdown by Category
Consulting$435,697 (83.1%)
Other$39,044 (7.4%)
Travel$25,362 (4.8%)
Research$23,007 (4.4%)
Food & Beverage$1,306 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $435,697 | 102 | 83.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $39,044 | 17 | 7.4% |
| Travel and Lodging | $25,362 | 32 | 4.8% |
| Unspecified | $23,007 | 11 | 4.4% |
| Food and Beverage | $1,306 | 15 | 0.2% |
Payments by Type
General
$501,408
166 transactions
Research
$23,007
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $178,084 | 19 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $133,167 | 72 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $93,743 | 32 | $0 (2023) |
| F. Hoffmann-La Roche AG | $52,206 | 28 | $0 (2024) |
| Horizon Therapeutics plc | $21,084 | 6 | $0 (2020) |
| Biogen, Inc. | $20,904 | 8 | $0 (2023) |
| Novartis Pharma AG | $13,557 | 7 | $0 (2020) |
| Bausch & Lomb Americas Inc. | $4,000 | 1 | $0 (2024) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $3,000 | 1 | $0 (2019) |
| Valeant Pharmaceuticals North America LLC | $2,500 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,653 | 4 | F. Hoffmann-La Roche AG ($12,653) |
| 2023 | $35,916 | 17 | Regeneron Pharmaceuticals, Inc. ($21,073) |
| 2022 | $25,487 | 10 | Biogen, Inc. ($13,274) |
| 2021 | $99,134 | 54 | Regeneron Pharmaceuticals, Inc. ($99,134) |
| 2020 | $25,994 | 12 | Horizon Therapeutics plc ($10,480) |
| 2019 | $79,755 | 21 | Genentech, Inc. ($58,363) |
| 2018 | $33,532 | 21 | F. Hoffmann-La Roche AG ($25,286) |
| 2017 | $207,945 | 38 | Genentech, Inc. ($109,784) |
All Payment Transactions
177 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $3,500.00 | Research |
| Study: RIDE Lucentis DME Phase III study | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,448.60 | Research |
| Study: Check A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION, A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION | ||||||
| 11/22/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA, LOTEMAX | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: Ophthalmology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $7,704.50 | Research |
| Study: RIDE Lucentis DME Phase III study | ||||||
| 11/03/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $1,058.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/18/2023 | Bayer Healthcare Pharmaceuticals Inc. | Adempas | Consulting Fee | Cash or cash equivalent | $1,392.00 | General |
| 08/25/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $4,320.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/25/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $2,970.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/25/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/25/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/25/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/25/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $1,080.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/25/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $1,080.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/25/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $540.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/11/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $2,390.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/11/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $2,390.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/11/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $1,195.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $5,131.00 | Research |
| Study: Check A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION, A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION | ||||||
| 06/09/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $2,150.00 | General |
| 04/05/2023 | Bayer Healthcare Pharmaceuticals Inc. | Adempas | Consulting Fee | Cash or cash equivalent | $1,392.00 | General |
| 02/06/2023 | Biogen, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,777.50 | General |
| 11/18/2022 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $5,400.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/29/2022 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| 09/29/2022 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $529.48 | General |
| 09/29/2022 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $34.36 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RIDE Lucentis DME Phase III study | F. Hoffmann-La Roche AG | $11,205 | 2 |
| Check A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION, A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION | F. Hoffmann-La Roche AG | $6,580 | 2 |
| Preliminary Safety and Efficacy of the PDS-1.0 in Patients With Neovascular Age Related Macular Degeneration AMD | F. Hoffmann-La Roche AG | $2,427 | 2 |
| A PHASE III, DOUBLE-MASKED, MULTICENTER, RANDOMIZED, SHAM INJECTION-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF RANIBIZUMAB INJECTION IN SUBJECTS WITH CLINICALLY SIGNIFICANT MACULAR EDEMA WITH CENTER INVOLVEMENT SECONDARY TO DIABETES MELLITUS, A PHASE III, DOUBLE-MASKED, MULTICENTER, RANDOMIZED, SHAM INJECTION-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF RANIBIZUMAB INJECTION IN SUBJECTS WITH CLINICALLY SIGNIFICANT MACULAR EDEMA WITH CENTER INVOLVEMENT SECONDARY TO DIABETES MELLITUS | F. Hoffmann-La Roche AG | $1,942 | 1 |
| A DOUBLE- MASKED, RANDOMIZED, ACTIVE-CONTROLLED, PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL ADMINISTRATION OF VEGF TRAP-EYE IN PATIENTS WITH DIABETIC MACULAR EDEMA | Regeneron Pharmaceuticals, Inc. | $772.54 | 3 |
| EYLEA CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $81.31 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 643 | 1,885 | $1.2M | $436,696 |
| 2022 | 6 | 712 | 2,171 | $1.3M | $536,087 |
| 2021 | 7 | 774 | 2,527 | $1.6M | $657,603 |
| 2020 | 7 | 871 | 2,421 | $1.7M | $701,177 |
Total Patients
3,000
Total Services
9,004
Medicare Billing
$2.3M
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 50 | 532 | $798,000 | $361,165 | 45.3% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 245 | 419 | $89,547 | $28,838 | 32.2% |
| 67028 | Injection of drug into eye | Office | 2023 | 50 | 248 | $168,178 | $24,667 | 14.7% |
| 92134 | Imaging of retina | Office | 2023 | 271 | 655 | $110,274 | $20,553 | 18.6% |
| 92002 | New patient problem focused exam of visual system | Office | 2023 | 13 | 13 | $3,012 | $957.84 | 31.8% |
| 92250 | Photography of the retina | Office | 2023 | 14 | 18 | $4,620 | $515.84 | 11.2% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 61 | 626 | $939,000 | $447,181 | 47.6% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 265 | 478 | $90,432 | $33,250 | 36.8% |
| 67028 | Injection of drug into eye | Office | 2022 | 62 | 282 | $177,850 | $29,189 | 16.4% |
| 92134 | Imaging of retina | Office | 2022 | 279 | 730 | $109,500 | $23,923 | 21.8% |
| 92002 | New patient problem focused exam of visual system | Office | 2022 | 18 | 18 | $3,681 | $1,356 | 36.8% |
| 92250 | Photography of the retina | Office | 2022 | 27 | 37 | $8,406 | $1,188 | 14.1% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 72 | 756 | $1.1M | $552,956 | 48.8% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2021 | 286 | 537 | $98,808 | $37,689 | 38.1% |
| 67028 | Injection of drug into eye | Office | 2021 | 73 | 339 | $210,345 | $36,050 | 17.1% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 289 | 830 | $124,500 | $27,002 | 21.7% |
| 92235 | Imaging of blood vessels in back of eye using fluorescein dye | Office | 2021 | 21 | 27 | $10,800 | $2,308 | 21.4% |
| 92002 | Eye and medical examination for diagnosis and treatment, new patient | Office | 2021 | 12 | 12 | $2,388 | $841.72 | 35.2% |
| 92250 | Photography of the retina | Office | 2021 | 21 | 26 | $5,772 | $755.04 | 13.1% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2020 | 76 | 810 | $1.2M | $600,948 | 49.5% |
| 67028 | Injection of drug into eye | Office | 2020 | 76 | 348 | $205,800 | $33,572 | 16.3% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2020 | 274 | 411 | $75,624 | $29,342 | 38.8% |
| 92134 | Diagnostic imaging of retina | Office | 2020 | 238 | 574 | $86,100 | $19,391 | 22.5% |
| 92235 | Imaging of blood vessels in back of eye using fluorescein dye | Office | 2020 | 104 | 167 | $66,800 | $13,447 | 20.1% |
| 92250 | Photography of the retina | Office | 2020 | 83 | 91 | $18,200 | $3,178 | 17.5% |
About Dr. Neil Bressler, M.D
Dr. Neil Bressler, M.D is a Ophthalmology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790742245.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Neil Bressler, M.D has received a total of $524,415 in payments from pharmaceutical and medical device companies, with $16,653 received in 2024. These payments were reported across 177 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($435,697).
As a Medicare-enrolled provider, Bressler has provided services to 3,000 Medicare beneficiaries, totaling 9,004 services with total Medicare billing of $2.3M. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Baltimore, MD
- Active Since 04/27/2006
- Last Updated 02/12/2013
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1790742245
Products in Payments
- Non-Covered Product (Drug) $178,759
- EYLEA (Biological) $133,167
- Eylea (Drug) $88,175
- Lucentis (Biological) $17,625
- RTH258A (Drug) $6,918
- QVJ499A_SIMBRINZA_OPHTHALMOLOGY (Biological) $5,806
- MIEBO (Drug) $4,000
- LOTEMAX (Drug) $3,000
- STELLARIS PC (Device) $2,500
- RTH258A_BEOVU_OPHTHALMOLOGY (Drug) $732.00
- QVJ499A (Biological) $101.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Baltimore
Dr. Alfred Sommer, M.d, M.D
Ophthalmology — Payments: $3.7M
Ophthalmology $3.7M
Peter Mcdonnell
Ophthalmology — Payments: $2.2M
Ophthalmology $2.2M
Esen Akpek, M.d, M.D
Ophthalmology — Payments: $627,113
Ophthalmology $627,113
Peter Campochiaro, M.d, M.D
Ophthalmology — Payments: $257,471
Ophthalmology $257,471
Jennifer Thorne, M.d, M.D
Ophthalmology — Payments: $201,745
Ophthalmology $201,745
Dr. Earl Craven, Md, MD
Ophthalmology — Payments: $187,007
Ophthalmology $187,007